 Angel Biotechnology Holdings Plc 
 
 
17 
DIRECTORS REMUNERATION REPORT 
Introduction 
 
The Company recognises the value of the Combined Code on Corporate Governance issued by the 
London Stock Exchange. It seeks to comply with the Combined Code so far as practicable and 
appropriate for a public company of its size and nature. The Company also seeks to follow the 
Corporate Governance Guidelines for AIM companies issued by the Quoted Companies Alliance in 
February 2007. 
 
The Remuneration Committee of the board is responsible for considering staff and Directors' 
remuneration packages and makes its recommendations to the board. The Committee comprises the 
Chairman and two non-executive Directors. It meets at least once a year to review salaries and share 
option schemes for staff and Directors. 
Remuneration policies 
 
Remuneration packages are designed to be competitive and to reward above average performances. 
At present Executive Directors receive salary and a 10-12% pension contribution. The Chief 
Operating Officer is entitled to a performance related bonus. He also holds 2 grants of share options, 
the first being issued prior to the Company being listed and a further grant during 2010. 
Service contracts 
 
The Executive Directors have executive service agreements with the Company dated 11 November 
2005. The service agreements are subject to termination with six months' notice being given by either 
party. 
Pensions 
 
The Company operates a defined contribution pension scheme for employees. 
Share Option Scheme 
 
The Company operates an HM Revenue & Customs approved EMI share option scheme that entitles 
directors, senior management and employees to purchase shares in the Company.   
 
Grants of share options have been awarded in 2005 and 2010.  The options are exercisable at the 
market price of the shares at the date of grant. 
 
During the year 31,276,422 share options were granted to directors resulting in an equity-settled 
share base payment charge to operating expenses of  29,000. 
  
Non-executive Directors 
 
The Non-Executive Directors have entered into letters of engagement with the Company. Members 
may request copies of these letters by sending a stamped addressed envelope to the Company 
Secretary. The appointments can be terminated upon six months' notice being given by either party.  
 
 
 
 
 
 
 
 
  Angel Biotechnology Holdings Plc 
 
 
18 
DIRECTORS REMUNERATION REPORT (continued) 
 
Directors' remuneration  
 
Details of Directors' remuneration in the year ended 31 December 2010 is set out below: 
 
 Salary 
  
Benefits 
  
Emoluments 
  
Pension 
  
Total 
  
      
Executive       
Dr P Harper 55,516 - 55,516 - 55,516 
G Sherriff      115,000  -       115,000       12,000 127,000 
      
Non-executive      
G Clark      12,938           -        12,938           -       12,938  
N Smith       12,000           -  12,000          -        12,000  
 ___________ ____________ ___________ ___________ __________ 
 
Total 
195,454 - 195,454 12,000 207,454 
 ========== ========== ========== ========== ========= 
 
One director is accruing benefits under the defined contribution pension scheme. 
 
 
Directors Share Options  
 
 Options at 
01.01.10 
 
Options 
granted in 
year 
 
Options at 
31.12.10 
 
Exercise 
Price 
(p) 
Exercise 
Period 
Expiry 
date 
Dr P Harper - 3,107,410 3,107,410 0.22 10 years 29/07/20 
G Sherriff - 16,901,408 16,901,408 0.22 10 years 29/07/20 
G Sherriff 550,000 - 550,000 0.5 10 years 19/07/15 
G Clark - 5,633,802 5,633,802 0.22 10 years 29/07/20 
N Smith - 5,633,802 5,633,802 0.22 10 years 29/07/20 
 
The market price of the shares at 31 December 2010 was 0.35p and the range during the year was 
0.17p to 0.46p 
 
 
 
By order of the board 
 
 
 
 
Dr Paul Harper 
Chairman 
 
25 February 2011 
 
 
 
 
 
 
 
 